Emergent BioSolutions (NYSE:EBS) will manufacture doses of Providence Therapeutics’ PTX-COVID19-B COVID-19 mRNA drug candidate under a five-year agreement. - The agreement is valued at $90M, and covers manufacturing services, studies to support global supply chain activities, and facility and equipment investments.
- Next year, Emergent will manufacture tens of millions of doses of PTX-COVID19-B, as well as batches of PTX-COVID19-B formulated bulk drug substance that can yield hundreds of millions more doses.
{iframe}https://seekingalpha.com/news/3739475-emergent-to-manufacture-providence-therapeutics-covid-19-mrna-vaccine-candidate{/iframe}